← All trials
NCT07000149
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 28, 2025
- Primary completion
- Feb 21, 2030
- Completion date
- Jul 29, 2032
- First posted
- Jun 2, 2025
- Last posted
- Nov 14, 2025
- Enrollment
- 1116
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- AstraZenecaLead sponsor
- Arcus Biosciences, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.